VFEN和MDM2在膀胱移行细胞癌中的表达和相互关系

Expressions of PTEN and MDM2 in Bladder Transitional Cell Carcinoma

目的 探讨PTEN和MDM2基因在膀胱移行细胞癌发生发展中的临床意义.方法 应用SP免疫组织化学染色法检测65例膀胱移行细胞癌中PTEN和MDM2基因的表达.结果 PTEN和MDM2在膀胱移行细胞癌的阳性率分别为47.69%（31/65）和69.23%（45/65）.随着病理分级、临床分期的增高,PTEN和MDM2的阳性率逐渐降低（P〈0.05）,在膀胱移行细胞癌中,PTEN和MDM2的表达呈明显负相关（r=-0.42,P＜0.05）.结论 膀胱移行细胞癌组织中PTEN和MDM2的异常表达在膀胱癌的进展中起重要作用,并有助于判断预后.

Objective To approach the gene expressions of and relationship between PTEN and MDM2 in bladder transitional cell carcinoma（BTCC） and their clinical significance. Methods Expression of PTEN and MDM2 in 65 cases with BTCC were detected by immunohistochemistry test （SP method）. Results The positive rates of PTEN and MDM2 were 47.69% （31/65） and 69.23% （45/65） respectively. The higher the pathological grade and the clinical stage were, the lower expressions of PTEN and MDM2 showed （ P 〈 0.05 ）. The expression of PTEN was negatively correlated with that of MDM2 in BTCC （r = - 0.42,P 〈 0.05 ）. Conclusion Expressions of PTEN and MDM2 play important roles in the progress of carcinoma and are helpful to evaluate the prognosis of patients.